Publicis Groupe: Third Quarter 2016 Revenue
bioMérieux – Business Review for the nine months ended September 30, 2016
WHO warns global tuberculosis fight is billions of dollars behind
Veeva Expands Clinical Leadership Team to Accelerate Next Phase of Innovation and Customer Success
New Report: Global mAb Biosimilars Market Spending to Grow at a CAGR of 4-7%, 2016-2020 - Key Vendors are Biocon, Celltrion, Dr. Reddy's Laboratories & Hospira - Research and Markets
GlaxoSmithKline GSK reported solid second-quarter results on Wednesday that were largely in line with our expectations, and we don't anticipate any changes to our fair value estimate. Sales increased 10% from the prior year driven by strong sales of asthma medicine Advair, diabetes medicine ...
This ETF holds a swath of large- and mid-cap U.S. healthcare companies.